LONG-TERM USE OF ASPIRIN: POSSIBLITIES OF OPTIMIZATION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the principles of long-term prevention of cardiovascular complications using acetylsalicylic acid (ASA). Careful determination of indications and choice of an appropriate dose allow to successfully improve patient’s prognosis. Arguments for the choice of a particular pharmaceutical form of ASA among the many available forms are presented.

Full Text

Restricted Access

About the authors

A. V Melekhov

FSBEI HE RNSMU n.a. N.I. Pirogov of RMH

Email: avmelekhov@gmail.com
PhD, Assistant Professor, Department of Hospital Therapy № 2 Moscow

References

  1. Mainous A.G., Tanner R.J., Shorr R.I., Limacher M.C. Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012. J. Am. Heart Assoc. 2014;3(4).
  2. Vandvik P., Lincoff A., Gore J.M., et al. Primary And Secondary Prevention Of Cardiovascular Disease. Chest. 2012;141(2_suppl):e637S-e668S.
  3. Piepoli M.F., Hoes A.W. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2016;37: 2315-81.
  4. Бритов А.Н., Поздняков Ю.М. и соавт. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. Приложение 2. 2011;10(6).
  5. ASCEND. A Study of Cardiovascular Events in Diabetes. http://www.ctsu.ox.ac.uk/ascend.
  6. De Berardis G., Sacco M., Evangelista V., Filippi A., Giorda C.B., Tognoni G., Valentini U., Nicolucci A. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.
  7. Nelson M.R., Reid C.M., Ames D.A., Beilin L.J., Donnan G.A., Gibbs P., Johnston C.I., Krum H., Storey E., Tonkin A., Wolfe R., Woods R., McNeil J.J. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med. J. Aust. 2008;189:105-9.
  8. Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) Trial. http://www.arrivestudy.com
  9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published erratum appears in BMJ 2002;324(7330):141] BMJ. 2002;324(7329):71-86.
  10. Antithrombotic Trialists' Collaboration, Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., Buring J., Hennekens C., Kearney P., Meade T., Patrono C., Roncaglioni M.C., Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60.
  11. VanWormer J.J., Greenlee R.T., McBride P.E., Peppard R.E., Malecki K.C., Che J., Nieto F.J. Aspirin for primary prevention of CVD: are the right people using it? J. Fam. Pract. 2012;61(9):525-32.
  12. Rodondi N., Cornuz J., Marques-Vidal P., Butler J., Hayoz D., Pécoud A., Paccaud F., Waeber G., Vollenweider P. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. Prev. Med. 2008;46(2):137-44.
  13. Loew D., Belz G.G. Acetylsalicylic acid (ASA) -How much, how often, and when? A clinical-pharmacological perspective. Int. J. Clin. Pharmacol. Ther. 2016;54(8):634-39.
  14. Bem D., Dretzke J., Stevens S., Lordkipanidzé M., Hodgkinson J., Bayliss S., Moore D., Fitzmaurice D. Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review. Syst. Rev. 2015;4:88.
  15. Patrono C., Coller B., Dalen J.E., FitzGerald G.A., Fuster V., Gent M., Hirsh J., Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119(1 Suppl):39S-63S.
  16. Lanas A., Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr. Med. Res. Opin. 2007;23(1):163-73.
  17. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А. Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. РЖГГК. 2012;22(1):87-9.
  18. Nema H., Kato M., Katsurada T., Nozaki Y., Yotsukura A., Yoshida I., Sato K., Kawai Y., Takagi Y., Okusa T., Takiguchi S., Sakurai M., Asaka M. Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease. J. Clin. Gastroenterol. 2009;43(2):130-32.
  19. Chowdhury A., Ganguly G., Chowdhury D., Santra A., Gupta J.D., Roy T. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study. Indian J. Gastroenterol. 2001;20(6):227-29.
  20. Takada M., Fujimoto M., Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int. J. Clin. Pharmacol. Ther. 2014;52(3):181-91.
  21. Endo H., Sakai E., Higurashi T., Yamada E., Ohkubo H., Iida H., Koide T., Yoneda M., Abe Y., Inamori M., Hosono K., Takahashi H., Kubota K., Nakajima A. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis. 2012;44(10):833-38.
  22. Hirata Y., Kataoka H., Shimura T., Mizushima T., Mizoshita T., Tanida S., Kamiya T., Joh T. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand. J. Gastroenterol. 2011;46(7-8):803-9.
  23. Мелехов А.В., Борисов С.Н. Эффективная и безопасная профилактика тромбообразования. Consilium medicum. 2013;15(5):88-92.
  24. Верткин А.Л., Аристархова О.Ю., Адонина Е.В. и др. Безопасность и фармакоэкономическая эффективность применения различных препаратов ацетилсалициловой кислоты у пациентов с ИБС. РМЖ. 2009;17(9):570-75.
  25. Баркаган З.С., Котовщикова Е.Ф. Сравнительный анализ основных и побочных эффектов различных форм ацетилсалициловой кислоты. Клин. фармакол. тер. 2004;13(3).
  26. Sagar K.A., Smyth M.R. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J. Pharm. Biomed. Anal. 1999;21(2):383-92.
  27. Grosser T., Fries S., Lawson J.A., Kapoor S.C., Grant G.R., FitzGerald G.A. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013;127(3):377-85.
  28. Eikelboom J., Hirsh J., White J., et al. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at risk of high for cardiovascular event. Circulation. 2002;105:1650-55.
  29. Patrignani P., Patrono C. Aspirin and Cancer. J. Am. Coll. Cardiol. 2016;68(9):967-76.
  30. Singh Ranger G. The role of aspirin in colorectal cancer chemoprevention. Crit. Rev. Oncol. Hematol. 2016;104:87-90.
  31. Prabhakaran D. SP 03-1 POLYPILL STRATEGY TO IMPROVED ADHERENCE. J. Hypertens. 2016;34 (Suppl 1):Abstract Book:e195.
  32. Российские рекомендации «Антитромботическая терапия у больных со стабильными проявлениями атеротромбоза». 2009.
  33. Российские рекомендации «Диагностика и лечение стабильной стенокардии». 2008.
  34. Рекомендации ESC/EACTS по реваскуляризации миокарда 2014. Рос. кардиол. журн. 2015;2(118):5-81.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies